© 1996 by Oxford University Press
Journal of the National Cancer Institute, Vol. 88, No. 21, 1580-1586,
November 6, 1996
© 1996 Oxford University Press
p53 Mutation and Locoregional Treatment Failure in Head and Neck Squamous Cell Carcinoma
Division of Head and Neck Cancer Research Department of Otolaryngology-Head and Neck Surgery, The Johns Hopkins Hospital Baltimore, MD
Department of Pathology, The Johns Hopkins Hospital Baltimore, MD
Department of Oncology, The Johns Hopkins Hospital Baltimore, MD
Division of Biostatistics, Department of Oncology, The Johns Hopkins Hospital Baltimore, MD
David Sidransky, M.D., 818 Ross Research Bldg., The Johns Hopkins Hospital, 720 Rutland Ave., Baltimore, MD 21205-2196.
Background: The p53 gene (also known as TP53) may be the most common genetic target involved in the malignant transformation of human cells. Direct sequence analysis has demonstrated that alteration of this gene occurs in approximately 45% of head and neck squamous cell carcinomas. The consequences of p53 mutations in these cancers with respect to tumor behavior and patient survival have not been rigorously determined. Purpose: We evaluated the implications of p53 mutations in relation to the control of locoregional disease and overall survival following radiation therapy. Methods: Data from 110 consecutive patients with invasive disease who were treated with primary radiation therapy (given with curative intent) or with adjuvant radiation therapy (following complete surgical extirpation of gross disease) were included in the analysis. A 1.8-kilobase fragment of the p53 gene encompassing exons 5–9 was amplified from the DNA of stored (frozen) tumor specimens; the amplified DNA was cloned and sequenced by use of standard techniques. Overall survival and locoregional disease-free survival after the completion of radiation therapy were estimated by the Kaplan-Meier method; survival comparisons were made by use of the logrank test or proportional hazards regression models. Reported P values are two-sided. Results: Forty-eight (44%) of the 110 tumors had cells bearing p53 mutations. The risk of locoregional recurrence following either primary or adjuvant radiation therapy was significantly greater (i.e., the time to recurrence was shorter) for patients whose tumors contained mutant p53 genes (univariate model hazard ratio [HR] for p53 mutation versus wild-type = 2.2; 95% confidence interval [CI] = 1.2–4.1; P =.02). The presence of regional lymph node metastases (presence versus absence, HR = 2.0; 95% CI = 1.0–4.2; P =.05) and treatment type (primary radiation therapy versus surgery plus adjuvant radiation therapy, HR = 2.3; 95% CI = 1.2–4.3; P = .01) were also associated with greater risks of locoregional failure. The presence of p53 mutations and lymph node metastases and treatment with primary, as opposed to adjuvant, radiation therapy remained significant risk factors in multivariate regression analysis. No relationship was demonstrated between p53 status and overall survival (mutant versus wild-type, HR = 1.1; 95% CI = 0.6–2.1; P = .66); however, a relationship was shown for tumor stage and overall survival (stages III and IV [more advanced] versus stages I and II [less advanced], HR = 3.3; 95% CI = 1.0–10.8; P = .05). Mutation of the p53 gene was not associated with patient age, sex, tumor stage, primary tumor site, regional lymph node status, degree of tumor cell differentiation, or treatment method. Conclusions: Mutation of the p53 gene is associated with an increased risk of locoregional failure in patients with invasive head and neck squamous cell carcinoma who are treated with radiation therapy. [J Natl Cancer Inst 1996;88:1580–6]
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  S. Choi and J.N. Myers Molecular Pathogenesis of Oral Squamous Cell Carcinoma: Implications for Therapy Journal of Dental Research, January 1, 2008; 87(1): 14 - 32. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. E. Couch, R. L. Ferris, J. A. Brennan, W. M. Koch, E. M. Jaffee, M. S. Leibowitz, G. T. Nepom, H. A. Erlich, and D. Sidransky Alteration of Cellular and Humoral Immunity by Mutant p53 Protein and Processed Mutant Peptide in Head and Neck Cancer Clin. Cancer Res., December 1, 2007; 13(23): 7199 - 7206. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. L. Lee, X. P. Yang, B. Yan, J. Friedman, P. Duggal, L. Bagain, G. Dong, N. T. Yeh, J. Wang, J. Zhou, et al. A Novel Nuclear Factor-{kappa}B Gene Signature Is Differentially Expressed in Head and Neck Squamous Cell Carcinomas in Association with TP53 Status Clin. Cancer Res., October 1, 2007; 13(19): 5680 - 5691. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Licitra, F. Perrone, P. Bossi, S. Suardi, L. Mariani, R. Artusi, M. Oggionni, C. Rossini, G. Cantu, M. Squadrelli, et al. High-Risk Human Papillomavirus Affects Prognosis in Patients With Surgically Treated Oropharyngeal Squamous Cell Carcinoma J. Clin. Oncol., December 20, 2006; 24(36): 5630 - 5636. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. R. Santos, M. Rodriguez-Pinilla, F. M. Vega, J. L. Rodriguez-Peralto, S. Blanco, A. Sevilla, A. Valbuena, T. Hernandez, A. J. van Wijnen, F. Li, et al. VRK1 Signaling Pathway in the Context of the Proliferation Phenotype in Head and Neck Squamous Cell Carcinoma Mol. Cancer Res., March 1, 2006; 4(3): 177 - 185. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Mueller, B. W. Schafer, S. Ferrari, M. Weibel, M. Makek, M. Hochli, and C. W. Heizmann The Calcium-binding Protein S100A2 Interacts with p53 and Modulates Its Transcriptional Activity J. Biol. Chem., August 12, 2005; 280(32): 29186 - 29193. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. A. Kyzas, K. T. Loizou, and J. P. A. Ioannidis Selective Reporting Biases in Cancer Prognostic Factor Studies J Natl Cancer Inst, July 20, 2005; 97(14): 1043 - 1055. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Vikhanskaya, M. M. Siddique, M. Kei Lee, M. Broggini, and K. Sabapathy Evaluation of the Combined Effect of p53 Codon 72 Polymorphism and Hotspot Mutations in Response to Anticancer Drugs Clin. Cancer Res., June 15, 2005; 11(12): 4348 - 4356. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Tokumaru, K. Yamashita, M. Osada, S. Nomoto, D.-I. Sun, Y. Xiao, M. O. Hoque, W. H. Westra, J. A. Califano, and D. Sidransky Inverse Correlation between Cyclin A1 Hypermethylation and p53 Mutation in Head and Neck Cancer Identified by Reversal of Epigenetic Silencing Cancer Res., September 1, 2004; 64(17): 5982 - 5987. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Ronchetti, C. B. Neglia, B. M. Cesana, N. Carboni, A. Neri, G. Pruneri, and L. Pignataro Association Between p53 Gene Mutations and Tobacco and Alcohol Exposure in Laryngeal Squamous Cell Carcinoma Arch Otolaryngol Head Neck Surg, March 1, 2004; 130(3): 303 - 306. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Licitra and J. B. Vermorken Is there still a role for neoadjuvant chemotherapy in head and neck cancer? Ann. Onc., January 1, 2004; 15(1): 7 - 11. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. A. Ginos, G. P. Page, B. S. Michalowicz, K. J. Patel, S. E. Volker, S. E. Pambuccian, F. G. Ondrey, G. L. Adams, and P. M. Gaffney Identification of a Gene Expression Signature Associated with Recurrent Disease in Squamous Cell Carcinoma of the Head and Neck Cancer Res., January 1, 2004; 64(1): 55 - 63. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. M. Rudin, E. E.W. Cohen, V. A. Papadimitrakopoulou, S. Silverman Jr, W. Recant, A. K. El-Naggar, K. Stenson, S. M. Lippman, W. K. Hong, and E. E. Vokes An Attenuated Adenovirus, ONYX-015, As Mouthwash Therapy for Premalignant Oral Dysplasia J. Clin. Oncol., December 15, 2003; 21(24): 4546 - 4552. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 O. Gallo, N. Schiavone, L. Papucci, I. Sardi, L. Magnelli, A. Franchi, E. Masini, and S. Capaccioli Down-Regulation of Nitric Oxide Synthase-2 and Cyclooxygenase-2 Pathways by p53 in Squamous Cell Carcinoma Am. J. Pathol., August 1, 2003; 163(2): 723 - 732. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Q.-T. Le, P. D. Sutphin, S. Raychaudhuri, S. C. T. Yu, D. J. Terris, H. S. Lin, B. Lum, H. A Pinto, A. C. Koong, and A. J. Giaccia Identification of Osteopontin as a Prognostic Plasma Marker for Head and Neck Squamous Cell Carcinomas Clin. Cancer Res., January 1, 2003; 9(1): 59 - 67. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. A. Geisler, A. F. Olshan, M. C. Weissler, J. Cai, W. K. Funkhouser, J. Smith, and K. Vick p16 and p53 Protein Expression as Prognostic Indicators of Survival and Disease Recurrence from Head and Neck Cancer Clin. Cancer Res., November 1, 2002; 8(11): 3445 - 3453. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Forastiere, W. Koch, A. Trotti, and D. Sidransky Head and Neck Cancer N. Engl. J. Med., December 27, 2001; 345(26): 1890 - 1900. [Full Text] [PDF]
|
|
|
|
|
|
N. Homann, M. Nees, C. Conradt, A. Dietz, H. Weidauer, H. Maier, and F. X. Bosch Overexpression of p53 in Tumor-distant Epithelia of Head and Neck Cancer Patients Is Associated with an Increased Incidence of Second Primary Carcinoma Clin. Cancer Res., February 1, 2001; 7(2): 290 - 296. [Abstract] [Full Text]
|
|
|
|
|
|
G. H. Yoo, J. Washington, M. Piechocki, J. Ensley, T. Shibuya, D. Oda, and W.-Z. Wei Progression of Head and Neck Cancer in an In Vitro Model Arch Otolaryngol Head Neck Surg, November 1, 2000; 126(11): 1313 - 1318. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. I. Shah, L. Yip, B. Greenberg, J. A. Califano, J. Chow, C. F. Eisenberger, D. J. Lee, D. A. Sewell, A. L. Reed, M. Lango, et al. Two Distinct Regions of Loss on Chromosome Arm 4q in Primary Head and Neck Squamous Cell Carcinoma Arch Otolaryngol Head Neck Surg, September 1, 2000; 126(9): 1073 - 1076. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C.-A. O. Nathan, K. Sanders, F. W. Abreo, R. Nassar, and J. Glass Correlation of p53 and the Proto-Oncogene eIF4E in Larynx Cancers: Prognostic Implications Cancer Res., July 1, 2000; 60(13): 3599 - 3604. [Abstract] [Full Text]
|
|
|
|
|
|
S. Temam, A. Flahault, S. Perie, G. Monceaux, F. Coulet, P. Callard, J.-F. Bernaudin, J. L. St Guily, and P. Fouret p53 Gene Status as a Predictor of Tumor Response to Induction Chemotherapy of Patients With Locoregionally Advanced Squamous Cell Carcinomas of the Head and Neck J. Clin. Oncol., January 14, 2000; 18(2): 385 - 385. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. J. Bova, D. I. Quinn, J. S. Nankervis, I. E. Cole, B. F. Sheridan, M. J. Jensen, G. J. Morgan, C. J. Hughes, and R. L. Sutherland Cyclin D1 and p16INK4A Expression Predict Reduced Survival in Carcinoma of the Anterior Tongue Clin. Cancer Res., October 1, 1999; 5(10): 2810 - 2819. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. E. Saunders, R. MacKenzie, R. Shipman, E. Fransen, R. Gilbert, and R. C. K. Jordan Patterns of p53 Gene Mutations in Head and Neck Cancer: Full-Length Gene Sequencing and Results of Primary Radiotherapy Clin. Cancer Res., September 1, 1999; 5(9): 2455 - 2463. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. L. Clayman, D. K. Frank, P. A. Bruso, and H. Goepfert Adenovirus-mediated Wild-Type p53 Gene Transfer as a Surgical Adjuvant in Advanced Head and Neck Cancers Clin. Cancer Res., July 1, 1999; 5(7): 1715 - 1722. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. R. Posner, P. G. Johnston, R. B. Tishler, J. Andersen, M. Fiorentino, P. M. Busse, L. A. Cavacini, A. D. Colevas, J. Clark, and C. M. Norris The Prognostic Value of Thymidylate Synthase and p53 Expression in Patients Treated with Induction Chemotherapy for Squamous Cell Carcinoma of the Head and Neck Oncologist, December 1, 1998; 3(6): 424 - 431. [Abstract] [Full Text]
|
|
|
|
|
|
C. H. Dunphy, F. R. Dunphy, J. H. Boyd, M. A. Varvares, H. J. Kim, V. Lowe, T. L. Dunleavy, J. Rodriguez, E. M. McDonough, and J. Minster Expression of p53 Protein in Advanced Head and Neck Squamous Cell Carcinoma Before and After Chemotherapy Arch Otolaryngol Head Neck Surg, November 1, 1997; 123(11): 1223 - 1225. [Abstract] [PDF]
|
|
|
|
 |
|
 M. E. Johns and J. K. Niparko Otolaryngology-Head and Neck Surgery JAMA, June 18, 1997; 277(23): 1886 - 1887. [PDF]
|
|